Antidepressants and the brain

International Clinical Psychopharmacology

Volumn 14, Issue SUPPL. 1, 1999, Pages

  Delgado, Pedro ^a   Moreno, Francisco ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Alpha methylparatyrosine; Depletion; Depression; Noradrenaline; Serotonin; Tryptophan

Indexed keywords

ANTIDEPRESSANT AGENT; CATECHOLAMINE; DESIPRAMINE; FLUOXETINE; METIROSINE; MONOAMINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN; TRYPTOPHAN;

BRAIN; CATECHOLAMINE BRAIN LEVEL; CATECHOLAMINE DEPLETION; CONFERENCE PAPER; DEPRESSION; HUMAN; MONOAMINE METABOLISM; NEUROCHEMISTRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER; HUMANS; NOREPINEPHRINE; SEROTONIN;

EID: 0032773369     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199905001-00003     Document Type: Conference Paper

References (63)

1. Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, Price LH (1994), Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 151:1626-1630.
2. Bakish D, Cavazzoni P, Chudzik J, Ravindran A, Hrdina PD (1997), Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 41:184-190.
3. 3H)nisoxetine autoradiography. Brain Res 582:208-214.
4. Bel N, Artigas F (1993). Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243-245.
5. Bel N, Artigas F (1996). Reduction of serotonergic function in rat brain by tryptophan depletion: effects in control and fluvoxamine-treuted rats. J Neurochemistry 67:669-676.
6. Briley MS, Langer SZ, Raisman R, Sechter D, Zarifian E (1980). Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science, 209:303-305,
7. Brodie HKH, Murphy DL, Goodwin FK, Bunney WH Jr (1971). Catecholamines and mania: the effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clin Pharmacol Ther 12:218-224.
8. 2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 70:1114-1123.
9. Carstens ME, Engelbrecht AH, Russell VA, Aalbers C, Gagiano CA, Chalton DO, Taljaard JJ (1986). Alpha 2-adrenoceptor levels on platelets of patients with major depressive disorders. Psychiatry Res 18:321-331.
10. Charney DS, Heninger GR, Sternberg D, Redmond DE, Leckman JF, Maas JW, Roth RH (1981). Presynaptic adrenergic receptor sensitivity in depression: the effect of long-term desipramine treatment. Arch Gen Psychiatry 38:1334-1340.
11. 1 binding sites in depressed suicides. Psychopharmacolagy 102:544-548.
12. Cheetham SC, Katona CLE, Horton RW (1991). Post-mortem studies of neurotransmitter biochemistry in depression and suicide. In: Biological aspects of affective disorders. Horton RW, Katona CLE (editors). London: Academic Press. pp. 192-221.
13. Coppen A, Eccleston EG, Peet M. (1973). Total and free tryptophan concentration in the plasma of depressed patients. Lancet ii;60-63.
14. Deakin JFW, Pennell I, Upadhyaya AJ, Lofthouse R (1990). A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology 101:85-92.
15. Delgado PL, Charney DS, Price LH, Landis H, Heninger GR (1989). Neuroendocrine and behavioral effects of dietary tryptophan depletion in healthy subjects. Life Sci 45:2323-2332.
16. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990). Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411-418.
17. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH (1991). Rapid scrotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and neurobiology of depression. Psychopharmacol Bull 27:321-330.
18. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gclenberg AJ, Charney DS (1993). Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 29:389-396.
19. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS (1994). Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874.
20. rd Annual Scientific Convention and Program. Toronto, Canada: Society of Biological Psychiatry. Ms # 973385.
21. Delgado PL, Moreno FA, Potter R, Gelenberg AJ (1998b). Norepinephrine and serotonin in antidepressant action: evidence from neurotransmitter depletion studies. In: Antidepressant therapy at the dawn of the third millennium. Briley M, Montgomery SA (editors). London: Martin Dunitz Ltd, pp. 141-163.
22. Engelman K, Horwitz D, Jequier E (1968). Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest 47:577-594.
23. García-Sevilla JA, Zis AP, Hollingsworth PJ, Greden JF, Smith CB (1981). Platelet alpha 2-adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Arch Gen Psychiatry 38:1327-1333.
24. 3H-imipramine binding in elderly depressed patients. Life Sci 40:2137-2143.
25. Gjerris A (1988). Baseline studies on transmitter substances in cerebrospinal fluid in depression. Acta Psychiatr Scand 78 (suppl 346):1-36.
26. Golden RN, Hsiao JK, Lane E, Ekstrom D, Rogers S, Hicks R, Potter WZ (1990). Abnormal neuroendocrine responsivity to acute IV clomipramine challenge in depressed patients. Psychiatry Res 31:39-47.
27. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
28. Healy D, Carney PA, Leonard BE (1983). Monoamine-related markers of depression: changes following treatment. J Psychiatric Res 17:251-260.
29. Healy D, Carney PA, O'Halloran A, Leonard BE (1985). Peripheral adrenoceptors and serotonin receptors in depression. J Affect Disord, 9:285-296.
30. 2A receptors unchanged by antidepressant treatment. Psychiatry Res 66:73-85.
31. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, Ordway GA (1997), Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 17:8451-8458.
32. Leonard BE (1997). Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 7 (suppl 1):S11-S16.
33. Maas JW, Fawcett JA, Dekirmenjiam H (1972). Catecholamine metabolism, depressive illness and drug response. Arch Gen Psychiatry 26:252-262.
34. Manji HK (1992). G-proteins: implications for psychiatry. Am J Psychiatry 149:746-760.
35. Mazure CM, Nelson JC, Price LH (1986). Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 43:451-456.
36. 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry 31,471-490.
37. Messing RB, Fisher LA, Phebus L, Lytle LD (1976). Interaction of diet and drugs in the regulation of brain 5-hydroxyindoles and the response to painful electric shock. Life Sci 18:707-714.
38. Miller HL, Delgado PL, Salomon RM, Herman R, Krystal JH, Hcninger GR, Charney DS (1996). Clinical and biochemical effects of catecholamine depiction on antidepressant-induced remission of depression. Arch Gen Psychiatry 53:127-128.
39. Mitchell P, Smythe G (1990). Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord 19:43-51.
40. Moja EA, Mendelson WB, Stoff DM, Gillian JC, Wyatt RJ (1979). Reduction of REM sleep by a tryptophan-free amino acid diet. Life Sci 24:1467-1470.
41. Moja EA, Cipollo P, Castoldi D, Tofanetti O (1989). Dose-response decrease in plasma tryptophan and in brain trytophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci 44:971-976.
42. Moreno FA, Delgado PL, McKnight K, Gelenberg AJ, Hcninger GR, Buonopane K, et al. (1996). Tryptophan depletion: a potential predictor of depressive episodes [abstract]. Washington, DC: 26th Annual Meeting of the Society for Neuroscience. Abstract 811.9.
43. Muscettola G, Potter WZ, Pickar D, Goodwin FK (1984). Urinary 3-methoxy-4-hydroxyphenyl-glycol and major affective disorders. Arch Gen Psychiatry 41:337-342.
44. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, et al. (1997). Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 94:5308-5313.
45. Nordström P, Åsberg M (1992). Suicide risk and serotonin. Int Clin Psychopharmacol 6:12-21.
46. Owens MJ, Nemeroff CB (1994). Role of serotonin in the pathophysiology of depression: focus on the serotonin receptor. Clin Chem 40:288-295.
47. Potter WZ, Muscettola G, Goodwin FK (1983). Sources of variance in clinical studies in MHPG. In: MHPG: basic mechanisms and basic psychopathology. Maas JW (editor). New York: Academic Press. pp. 145-165.
48. Racagni G, Brunello N, Tinelli D, Perez J (1992). New biochemical hypotheses on the mechanism of action of antidepressant drugs: cAMP-dependent phosphorylation system. Pharmacopsychiatry 25:51-55.
49. Rose WC, Haines WJ, Warner DT (1954). The amino acid requirements of man. J Biological Chem 206:421-430.
50. Schatzberg AF, Samson JA, Bloomingdale KL, Orsulak PJ, Gerson B, Kizuka PP, et al. (1989). Towards a biochemical classification of depressive disorders. X. Urinary catecholamines, their metabolites and D-type scores in subgroups of depressive disorders. Arch Gen Psychiatry 46:260-268.
51. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, LaBrie RA (1978). Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Arch Gen Psychiatry 35:1427-1433.
52. Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S (1975). Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1:239-249.
53. Shopsin B, Friedman E, Gershon S (1976). Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 33:811-891.
54. Sjoerdsma A, Engelman K, Spector S (1965). Inhibition of catecholamine synthesis in man with alpha methyl tyrosine, an inhibitor of tyrosine hydroxylase. Lancet, ii:1092-1094.
55. Smith KA, Fairburn CG, Cowen PJ (1997). Relapse of depression after rapid depletion of tryptophan. Lancet 349:915-919.
56. Spyraki C, Fibiger HC (1980). Functional evidence for subsensitivity of noradrenergic alpha 2 receptors after chronic desipramine treatment. Life Sci 27:1863-1867.
57. Stahl SM (1998). Basic psychopharmacology of antidepressants, Pan I: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 59 (suppl 4):5-14.
58. Stanley M, Mann JJ (1983). Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet i:214-216.
59. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G (1998). Increase in serotonin 1A autoreceptors in the midbrain of suicide victims with major depression - postmortem evidence for decreased serotonin activity. J Neurosci 18:7394-7401.
60. Walters JK, Davis M, Sheard MH (1979). Tryptophan-free diet: effects on the acoustic startle reflex in rats. Psychopharmticology 62:103-109.
61. 2-adrenergic receptors in depressed patients and healthy volunteers: the effects of desipramine. Pharmacopsychiatry 25:199-206.
62. Widerlov E, Lewander T (1978). Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after α-methyl-p-tyrosine: time- and dose-response relationships. Naunyn-Schmiedeberg's Arch Pharmacol 304:111-123.
63. Young SN, Ervin FR, Pihl RO, Finn P (1989). Biochemical aspects of tryptophan depletion in primates. Psychopharmacology 98:508-511.